on February 28, 2023 SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, reported that Synergy Oncology, part of Synergy Laboratories, a full-service diagnostic laboratory based in Mobile, Alabama, will use SOPHiA DDM to develop a new cancer profiling solution (Press release, Sophia Genetics, FEB 28, 2023, View Source [SID1234627934]). The combination of technology from Synergy Oncology and SOPHiA GENETICS will expand Synergy’s oncology portfolio while helping to further the U.S. oncology market.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Synergy Oncology, which specializes in the use of innovative platforms to improve patient care, will pair SOPHiA DDM for Hereditary Cancers Solution with their state-of-the-art laboratory technologies to launch Totality, a comprehensive end-to-end solution for tumor profiling that will benefit cancer research, clinical studies, and patient care.
"Our mission at SOPHiA GENETICS is to democratize data-driven medicine by increasing accessibility to synthesized, digestible data in this space," said Ken Freedman, Chief Revenue Officer, SOPHiA GENETICS. "Synergy is known to be a best-in-class facility and their use of the SOPHiA DDM is an important step in creating cancer profiling solutions that will progress research and treatments of hereditary cancers for the medical community."
"Our decision to collaborate with SOPHiA GENETICS was simple," said Joseph Cohil, Head of Synergy Oncology. "Our collaboration with SOPHiA GENETICS will accelerate Synergy’s leading hereditary cancer technology to the forefront of patient outcomes."
The use of next generation sequencing (NGS) is prevalent in the detection of biomarkers for hereditary cancers but comes with a vast and complex dataset for analysis. The SOPHiA DDM for Hereditary Cancers Solution uses Artificial Intelligence and machine learning with patented technologies to analyze raw NGS data, streamlining it for simplified interpretation, and expedited reporting. The SOPHiA DDM platform can serve as a one-stop solution for Synergy Laboratories as it looks to scale into other oncology offerings.
Synergy’s new Totality product analyzes genes from solid tumor tissue, and through the use of SOPHiA DDM for Hereditary Cancers, it provides physicians with a compact report that matches detected molecular alterations with FDA approved therapies and clinical trials. The pairing of SOPHiA DDM for Hereditary Cancers with Synergy Oncology’s technology is designed to give experts the ability to analyze and interpret findings from NGS data with confidence, turning high-quality data into valuable insights for researchers and care providers. Synergy Oncology offers the most comprehensive NGS kit of its kind, including liquid biopsy testing, hereditary testing, and myeloid malignancies.